Table 4 Descriptive statistics for the pharmacoeconomic variables used in this study with data from meta-analysis and estimated by the expert panel
Assessment | Mean | SEM | Median | SD | Variance | Min | Max | 25th Pctl | 75th Pctl |
|---|---|---|---|---|---|---|---|---|---|
OM-85 | |||||||||
Effectiveness | 0.466 | 0.002 | 0.467 | 0.049 | 0.002 | 0.38 | 0.55 | 0.424 | 0.508 |
Tx without IS, n | 5.6 | 0.01 | 5.59 | 0.29 | 0.09 | 4.93 | 6.3 | 5.37 | 5.85 |
Tx with OM-85, n | 2.99 | 0.01 | 2.97 | 0.32 | 0.1 | 2.31 | 3.83 | 2.74 | 3.24 |
Incremental ARTIs, n | −2.61 | 0.01 | −2.6 | 0.31 | 0.09 | −3.4 | −1.9 | −2.82 | − 2.38 |
Direct Costs ($MXN) | |||||||||
Tx without IS | 1140.8 | 15.1 | 1124.2 | 478.7 | 229,163 | 180 | 2149.1 | 742.1 | 1527.8 |
Tx with OM-85 | 970.6 | 8.5 | 965.1 | 268.8 | 72,235 | 370.6 | 1647.9 | 746.9 | 1178.5 |
Incremental | −170.2 | 7.4 | −154.6 | 235.1 | 55,282.5 | − 839.4 | 316.1 | −341.5 | 14.9 |
Cost-Effectiveness | −358.8 | 15.6 | − 326.7 | 493.1 | 243,194 | − 1528.9 | 756.2 | −729.5 | 33.1 |
Direct Cost + Absenteeism ($MXN) | |||||||||
Tx without IS | 2515.1 | 20.5 | 2495.4 | 648.1 | 419,984 | 944.5 | 4140.4 | 2056.5 | 3003.1 |
Tx with OM-85 | 1704.1 | 11.8 | 1681.2 | 373 | 139,107 | 853.9 | 2758.8 | 1442.9 | 1976.2 |
Incremental | −811 | 23.3 | − 790 | 737.8 | 544,411 | − 2722.1 | 1490.8 | −1365.8 | −279 |
Cost-Effectiveness | −1737.8 | 50.8 | − 1662.5 | 1606.4 | 2,580,387 | − 6705.7 | 3566.4 | −2847.3 | −586.7 |